Table 1.
General characteristics of the study population
| Arbekacin (n = 73) | Vancomycin (n = 73) | p-value | |
|---|---|---|---|
| Age (years) | 54.1 ± 16.4 | 56.3 ± 14.7 | 0.397 |
| Sex | |||
| Male | 43 (58.9%) | 43 (58.9%) | 1.000 |
| Female | 30 (41.1%) | 30 (41.1%) | |
| Department | |||
| Medical | 15 (20.5%) | 38 (52.1%) | <0.001 |
| Surgical | 58 (79.5%) | 35 (47.9%) | |
| Clinical status | |||
| Sepsis | 5 (6.8%) | 6 (8.2%) | 0.063 |
| Wound- and catheter-related | 45 (61.6%) | 31 (42.5%) | |
| Othersa | 23 (31.5%) | 36 (49.3%) | |
| Medication duration (days) | 19.4 ± 15.7 | 18.2 ± 11.3 | 0.608 |
aOtitis media (13), meningitis (6), pneumonia (29), peritonitis (6), urinary tract infection (UTI), cellulitis, neutropenic fever (1)
Analyzed by the t-test and the Chi-squared test